Faropenem Catalog No.:M16831-C The development of CNS-active LRRK2

The development of CNS-active LRRK2 inhibitors using property-directed optimisation

Formula: C19H22N2O3S

5-dioxopentan-2-yl]pentanediamide

activation of coagulation factors V

5 μM) potentiates the apoptosis induced by TNF and chemotherapeutic agents and inhibits invasion

Faropenem Catalog No.:M16831-C The development of CNS-active LRRK2Faropenem is a potent and orally active beta lactam antibiotic. Faropenem demonstrates broad spectrum in vitro antimicrobial activity against many gram positive and negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta lactamases, including extended spectrum beta lactamases and AmpC beta lactamases. Faropenem is developed as an oral prodrug, faropenem medoxomil, for the research of respiratory tract infections.